Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Update Il y a 4 ans
Reference: NCT01562821

Woman and Man

Extract

This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.


Inclusion criteria

  • Acquired Bleeding Disorder ,Cirrhosis

Links